These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17476276)

  • 1. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera.
    Tefferi A; Strand JJ; Lasho TL; Knudson RA; Finke CM; Gangat N; Pardanani A; Hanson CA; Ketterling RP
    Leukemia; 2007 Sep; 21(9):2074-5. PubMed ID: 17476276
    [No Abstract]   [Full Text] [Related]  

  • 2. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
    Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
    APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates.
    Gangat N; Strand J; Lasho TL; Finke CM; Knudson RA; Pardanani A; Li CY; Ketterling RP; Tefferi A
    Eur J Haematol; 2008 Mar; 80(3):197-200. PubMed ID: 18081705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
    Sirhan S; Lasho TL; Hanson CA; Mesa RA; Pardanani A; Tefferi A
    Am J Hematol; 2008 May; 83(5):363-5. PubMed ID: 18266209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.
    Pardanani A; Lasho TL; Finke C; Hanson CA; Tefferi A
    Leukemia; 2007 Sep; 21(9):1960-3. PubMed ID: 17597810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?
    Verstovsek S; Silver RT; Cross NC; Tefferi A
    Leukemia; 2006 Nov; 20(11):2067. PubMed ID: 16990780
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
    Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
    Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2V617F mutation in a 9-year-old girl with polycythemia vera and Budd-Chiari syndrome: a case report.
    Benedik-Dolničar M; Homan M; Brecelj J
    J Pediatr Hematol Oncol; 2012 Apr; 34(3):243-4. PubMed ID: 21552144
    [No Abstract]   [Full Text] [Related]  

  • 9. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.
    Passamonti F; Rumi E; Pietra D; Elena C; Boveri E; Arcaini L; Roncoroni E; Astori C; Merli M; Boggi S; Pascutto C; Lazzarino M; Cazzola M
    Leukemia; 2010 Sep; 24(9):1574-9. PubMed ID: 20631743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlations of JAK2V617F point mutation with clinical and laboratory features in patients with polycythemia vera].
    Shen YF; Xia J; Lu MZ; Jiang YQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):121-4. PubMed ID: 19236761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
    Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
    Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Leukemia; 2008 Jan; 22(1):194-5. PubMed ID: 17625603
    [No Abstract]   [Full Text] [Related]  

  • 13. Lu/BCAM-mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients.
    De Grandis M; Cassinat B; Kiladjian JJ; Chomienne C; El Nemer W
    Am J Hematol; 2015 Jul; 90(7):E137-8. PubMed ID: 25809027
    [No Abstract]   [Full Text] [Related]  

  • 14. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden.
    Vannucchi AM; Antonioli E; Guglielmelli P; Longo G; Pancrazzi A; Ponziani V; Bogani C; Ferrini PR; Rambaldi A; Guerini V; Bosi A; Barbui T;
    Leukemia; 2007 Sep; 21(9):1952-9. PubMed ID: 17625606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice.
    Ishii T; Zhao Y; Sozer S; Shi J; Zhang W; Hoffman R; Xu M
    Exp Hematol; 2007 Nov; 35(11):1633-40. PubMed ID: 17764815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.
    Guglielmelli P; Barosi G; Pieri L; Antonioli E; Bosi A; Vannucchi AM
    Haematologica; 2009 Jan; 94(1):144-6. PubMed ID: 19042918
    [No Abstract]   [Full Text] [Related]  

  • 18. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alvarez-Larrán A; Angona A; Martínez-Avilés L; Bellosillo B; Besses C
    Leuk Res; 2012 Mar; 36(3):324-6. PubMed ID: 22001278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.
    Lakey MA; Pardanani A; Hoyer JD; Nguyen PL; Lasho TL; Tefferi A; Hanson CA
    Am J Clin Pathol; 2010 Jun; 133(6):942-8. PubMed ID: 20472853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.